Mereo Biopharma Group Stock Price Prediction
| MREO Stock | USD 3.56 0.16 4.71% |
Oversold Vs Overbought
42
Oversold | Overbought |
EPS Estimate Current Year (0.03) | Wall Street Target Price 7.22 |
Using Mereo BioPharma hype-based prediction, you can estimate the value of Mereo BioPharma Group from the perspective of Mereo BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Mereo BioPharma using Mereo BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Mereo using crowd psychology based on the activity and movement of Mereo BioPharma's stock price.
Mereo BioPharma Implied Volatility | 1.66 |
Mereo BioPharma's implied volatility exposes the market's sentiment of Mereo BioPharma Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mereo BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mereo BioPharma stock will not fluctuate a lot when Mereo BioPharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Mereo BioPharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Mereo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Mereo BioPharma after-hype prediction price | USD 3.57 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Mereo |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mereo BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mereo BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Mereo BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Mereo BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Mereo BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Mereo BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Mereo BioPharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mereo BioPharma's historical news coverage. Mereo BioPharma's after-hype downside and upside margins for the prediction period are 0.18 and 7.21, respectively. We have considered Mereo BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Mereo BioPharma is relatively risky at this time. Analysis and calculation of next after-hype price of Mereo BioPharma Group is based on 3 months time horizon.
Mereo BioPharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Mereo BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Mereo BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.37 | 3.65 | 0.01 | 0.22 | 8 Events / Month | 8 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.56 | 3.57 | 0.28 |
|
Mereo BioPharma Hype Timeline
Mereo BioPharma Group is now traded for 3.56. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.22. Mereo is forecasted to increase in value after the next headline, with the price projected to jump to 3.57 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.28%, whereas the daily expected return is now at -0.37%. The volatility of related hype on Mereo BioPharma is about 628.11%, with the expected price after the next announcement by competition of 3.34. The company reported the previous year's revenue of 10 M. Net Loss for the year was (29.47 M) with profit before overhead, payroll, taxes, and interest of 936 K. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Mereo BioPharma Basic Forecasting Models to cross-verify your projections.Mereo BioPharma Related Hype Analysis
Having access to credible news sources related to Mereo BioPharma's direct competition is more important than ever and may enhance your ability to predict Mereo BioPharma's future price movements. Getting to know how Mereo BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Mereo BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DRUG | Bright Minds Biosciences | (9.63) | 9 per month | 4.62 | 0.14 | 9.23 | (11.87) | 1,471 | |
| HPQ | HP Inc | 0.51 | 9 per month | 1.62 | 0.02 | 2.22 | (2.63) | 6.13 | |
| INTC | Intel | (0.30) | 6 per month | 2.58 | 0.06 | 6.36 | (3.50) | 18.29 | |
| CVX | Chevron Corp | 1.42 | 6 per month | 1.05 | 0.02 | 2.21 | (1.79) | 5.13 | |
| KO | The Coca Cola | 0.69 | 8 per month | 0.00 | (0.30) | 1.11 | (1.66) | 4.00 | |
| TRV | The Travelers Companies | (0.41) | 7 per month | 1.17 | 0.09 | 1.93 | (2.17) | 11.31 | |
| JNJ | Johnson Johnson | 0.08 | 7 per month | 0.00 | (0.26) | 1.40 | (1.42) | 3.25 | |
| JPM | JPMorgan Chase Co | (2.36) | 8 per month | 1.42 | 0.05 | 2.05 | (2.00) | 15.87 | |
| MSFT | Microsoft | 4.77 | 8 per month | 1.49 | (0.05) | 2.09 | (1.85) | 8.19 |
Mereo BioPharma Additional Predictive Modules
Most predictive techniques to examine Mereo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mereo using various technical indicators. When you analyze Mereo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Mereo BioPharma Predictive Indicators
The successful prediction of Mereo BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mereo BioPharma Group, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mereo BioPharma based on analysis of Mereo BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mereo BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mereo BioPharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 0.3 | 0.36 | 0.28 | 0.26 | Receivables Turnover | 25.7 | 0.55 | 2.68 | 2.55 |
Story Coverage note for Mereo BioPharma
The number of cover stories for Mereo BioPharma depends on current market conditions and Mereo BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Mereo BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Mereo BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Mereo BioPharma Short Properties
Mereo BioPharma's future price predictability will typically decrease when Mereo BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Mereo BioPharma Group often depends not only on the future outlook of the potential Mereo BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mereo BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 659.5 M | |
| Cash And Short Term Investments | 57.4 M |
Check out Mereo BioPharma Basic Forecasting Models to cross-verify your projections. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.